Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed Aug 14, 2024
- Accession no.
- 0001104659-24-089639
- Filed
- Aug 14, 2024
- Trade date
- Aug 12-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.28M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | Ordinary Shares | SSaleDisposed | −1,600 | $3.13F3 | −$5,008 | 15,338,088 | Direct | |
| Aug 13, 2024 | Ordinary Shares | SSaleDisposed | −394,664 | $3.20F4 | −$1,262,924.8 | 14,943,424 | Direct | |
| Aug 13, 2024 | Ordinary Shares | SSaleDisposed | −3,736 | $3.25F3 | −$12,142 | 14,939,688 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the ADS sale price on the Nasdaq Stock Market LLC divided by eight (8).
Referenced by the price of 2 transactions in Table I.
- F4
The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $3.125 to $3.24625 per Ordinary Share, inclusive (or $25.00 to $25.97 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.